{{medical}}
{{Infobox drug|drug_name=|ChemSpiderID=32055842|legal_UN=<!-- N I, II, III, IV / P I, II, III, IV-->|legal_status=Rx-only

<!-- Pharmacokinetic data -->|bioavailability=|protein_bound=|metabolism=|metabolites=|onset=|elimination_half-life=|duration_of_action=|excretion=<!-- Identifiers -->|CAS_number=1254053-43-4|PubChem=49803313|legal_EU=Rx-only|ChEBI=145372|DrugBank=DB12141|UNII=66D92MGC8M|KEGG=D10709|KEGG2=D10800

<!-- Chemical and physical data -->|IUPAC_name=6-Ethyl-3-[3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]anilino]-5-(oxan-4-ylamino)pyrazine-2-carboxamide|C=29|H=44|N=8|O=3|SMILES=CCc1nc(C(=O)N)c(Nc2ccc(N3CCC(CC3)N4CCN(C)CC4)c(OC)c2)nc1NC5CCOCC5|StdInChI=1S/C29H44N8O3/c1-4-23-28(31-20-9-17-40-18-10-20)34-29(26(33-23)27(30)38)32-21-5-6-24(25(19-21)39-3)37-11-7-22(8-12-37)36-15-13-35(2)14-16-36/h5-6,19-20,22H,4,7-18H2,1-3H3,(H2,30,38)(H2,31,32,34)|legal_EU_comment=<ref name="Xospata EPAR">{{cite web | title=Xospata EPAR | website=[[欧洲药品管理局|European Medicines Agency]] (EMA) | date=2019-09-16 | url=https://www.ema.europa.eu/en/medicines/human/EPAR/xospata | access-date=2020-08-16 | archive-date=2020-12-09 | archive-url=https://web.archive.org/web/20201209005805/https://www.ema.europa.eu/en/medicines/human/EPAR/xospata | dead-url=no }}</ref>|legal_US_comment=<ref name="Xospata FDA label">{{cite web | title=Xospata- gilteritinib tablet | website=DailyMed | date=2019-05-31 | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b5ff59aa-9c0d-49a8-9053-1f179b482383 | access-date=2020-08-16 | archive-date=2020-12-09 | archive-url=https://web.archive.org/web/20201209084939/https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b5ff59aa-9c0d-49a8-9053-1f179b482383 | dead-url=no }}</ref>|INN=|pregnancy_US=N|type=<!-- empty -->|image=Gilteritinib.svg|alt=|caption=<!-- Clinical data -->|pronounce=|tradename=Xospata|Drugs.com={{Drugs.com|monograph|gilteritinib-fumarate}}|MedlinePlus=a619003|DailyMedID=Gilteritinib|pregnancy_AU=D|pregnancy_AU_comment=<ref name="Xospata APMDS">{{cite web | title=Xospata Australian prescription medicine decision summary | website=Therapeutic Goods Administration (TGA) | date=2020-04-11 | url=https://www.tga.gov.au/apm-summary/xospata | access-date=2020-08-16 | archive-date=2020-12-10 | archive-url=https://web.archive.org/web/20201210020526/https://www.tga.gov.au/apm-summary/xospata | dead-url=no }}</ref>|pregnancy_US_comment=<ref name="Drugs.com pregnancy">{{cite web | title=Gilteritinib (Xospata) Use During Pregnancy | website=Drugs.com | date=2019-08-20 | url=https://www.drugs.com/pregnancy/gilteritinib.html | access-date=2020-08-16 | archive-date=2020-10-21 | archive-url=https://web.archive.org/web/20201021191728/https://www.drugs.com/pregnancy/gilteritinib.html | dead-url=no }}</ref>|legal_US=Rx-only|pregnancy_category=|routes_of_administration=[[口服给药|口服]]|ATCvet=|ATC_prefix=L01|ATC_suffix=XE54 <!-- scheduled to be L01EX13 in 2021 -->|legal_AU=S4|legal_AU_comment=<ref name="Xospata APMDS" />|legal_CA=<!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII -->|legal_DE=<!-- Anlage I, II, III -->|legal_NZ=<!-- Class A, B, C -->|legal_UK=POM|legal_UK_comment=<ref>{{cite web | title=Xospata 40 mg film-coated tablets - Summary of Product Characteristics (SmPC) | website=(emc) | date=2019-11-13 | url=https://www.medicines.org.uk/emc/product/10832/smpc | access-date=2020-08-16 | archive-date=2020-12-08 | archive-url=https://web.archive.org/web/20201208140836/https://www.medicines.org.uk/emc/product/10832/smpc | dead-url=no }}</ref>|StdInChIKey=GYQYAJJFPNQOOW-UHFFFAOYSA-N}}

'''吉瑞替尼'''（{{lang-en|Gilteritinib}}），以商品名'''Xospata'''出售，是一種抗癌藥。<ref>{{Cite journal|title=Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study|date=August 2017|journal=The Lancet. Oncology|issue=8|doi=10.1016/S1470-2045(17)30416-3|volume=18|pages=1061–1075|pmc=5572576|pmid=28645776|display-authors=6}}</ref>它可作為AXL受體酪胺酸激酶抑制劑，因此是一種[[酪氨酸激酶抑制劑|酪氨酸激酶抑制劑]]。 <ref>{{Cite journal|title=Preclinical studies of gilteritinib, a next-generation FLT3 inhibitor|date=January 2017|journal=Blood|issue=2|doi=10.1182/blood-2016-10-745133|volume=129|pages=257–260|pmc=5234222|pmid=27908881|display-authors=6}}</ref>

此藥由[[安斯泰來製藥|安斯泰來製藥]]（Astellas Pharma）[[药物研发|開發]]。

2018年4月，安斯泰來向[[美国食品药品监督管理局|美國食品藥品監督管理局]]（FDA）申请了吉瑞替尼的新藥申請，用於治療復發或難治性{{tsl|en|FLT3||FLT3}}突變[[急性骨髓性白血病|急性骨髓性白血病]]成年患者。<ref>{{Cite news|url=https://www.onclive.com/web-exclusives/fda-approval-sought-for-gilteritinib-in-flt3-aml|publisher=onclive.com|title=FDA Approval Sought for Gilteritinib in FLT3+ AML|date=2018-04-24|accessdate=2018-09-29|archive-date=2018-09-29|archive-url=https://web.archive.org/web/20180929194717/https://www.onclive.com/web-exclusives/fda-approval-sought-for-gilteritinib-in-flt3-aml|dead-url=no}}</ref>

2018年11月，[[美国食品药品监督管理局|美國FDA]]批准吉瑞替尼作為復發或難治性FLT3突變[[急性骨髓性白血病|急性骨髓性白血病]]成年患者的治療用藥；FLT3突變須由[[美国食品药品监督管理局|美國FDA]]批准的測試測出。<ref name="fda-gilteritinib-2018-11-28">{{Cite web|title=FDA approves gilteritinib for relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation|url=https://www.fda.gov/drugs/fda-approves-gilteritinib-relapsed-or-refractory-acute-myeloid-leukemia-aml-flt3-mutatation|accessdate=2018-11-29|date=2018-11-28|work=U.S. [[美国食品药品监督管理局|Food and Drug Administration]] (FDA)|archive-date=2020-12-22|archive-url=https://web.archive.org/web/20201222064639/https://www.fda.gov/drugs/fda-approves-gilteritinib-relapsed-or-refractory-acute-myeloid-leukemia-aml-flt3-mutatation|dead-url=no}}</ref><ref>{{Cite web|title=Xospata EPAR|url=https://www.ema.europa.eu/en/medicines/human/EPAR/xospata|accessdate=2020-08-16|author=|date=2019-09-16|format=|publisher=European Medicines Agency (EMA).|language=|archive-date=2020-12-09|archive-url=https://web.archive.org/web/20201209005805/https://www.ema.europa.eu/en/medicines/human/EPAR/xospata|dead-url=no}}</ref>

[[美国食品药品监督管理局|美國FDA]]、歐洲聯盟委員會、以及日本厚生勞動省授權吉瑞替尼作為某些急性骨髓白血病患者的罕用藥。<ref>{{Cite web|title=U.S. FDA Grants Priority Review to Astellas' New Drug Application for Gilteritinib for the Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)|url=https://www.drugs.com/nda/gilteritinib_180529.html|accessdate=2018-12-03|work=Drugs.com|archive-date=2020-12-09|archive-url=https://web.archive.org/web/20201209201053/https://www.drugs.com/nda/gilteritinib_180529.html|dead-url=no}}</ref>

2020年三月，吉瑞替尼被批准在澳洲用於醫療。<ref>{{Cite web|title=AusPAR: Gilteritinib (as fumarate)|url=https://www.tga.gov.au/auspar/auspar-gilteritinib-fumarate|accessdate=2020-09-23|date=2020-09-11|work={{tsl|en|Therapeutic Goods Administration||Therapeutic Goods Administration}} (TGA)|archive-date=2020-12-10|archive-url=https://web.archive.org/web/20201210180648/https://www.tga.gov.au/auspar/auspar-gilteritinib-fumarate|dead-url=no}}</ref>

== 研究 ==
吉瑞替尼的用途已被重新定位為有潛力的抗病毒藥物，可能可以應用在治療[[嚴重特殊傳染性肺炎|COVID-19]]上。<ref>{{Cite journal|title=The Global Phosphorylation Landscape of SARS-CoV-2 Infection|url=https://www.cell.com/cell/fulltext/S0092-8674(20)30811-4|date=2020-08-06|journal=Cell|accessdate=2020-07-24|issue=3|doi=10.1016/j.cell.2020.06.034|volume=182|pages=685–712.e19|pmc=7321036|pmid=32645325|display-authors=5|archive-date=2020-09-29|archive-url=https://web.archive.org/web/20200929232953/https://www.cell.com/cell/fulltext/S0092-8674(20)30811-4|dead-url=no}}</ref>

== 參考文獻 ==
{{Reflist}}

== 延伸閱讀 ==

* {{Cite report|url=https://www.tga.gov.au/auspar/auspar-gilteritinib-fumarate|title=AusPAR: Gilteritinib (as fumarate)|last=|first=|date=September 2020|issue=|doi=|volume=|pmid=|access-date=|website={{tsl|en|Therapeutic Goods Administration||Therapeutic Goods Administration}} (TGA)|archive-date=2020-12-10|archive-url=https://web.archive.org/web/20201210180648/https://www.tga.gov.au/auspar/auspar-gilteritinib-fumarate|dead-url=no}}

== 外部連結 ==

* {{Cite web|title=Gilteritinib|url=https://druginfo.nlm.nih.gov/drugportal/name/gilteritinib|work=Drug Information Portal|publisher=U.S. National Library of Medicine|access-date=2020-11-29|archive-date=2020-12-09|archive-url=https://web.archive.org/web/20201209113945/https://druginfo.nlm.nih.gov/drugportal/name/gilteritinib|dead-url=no}}
* {{Cite web|title=Gilteritinib fumarate|url=https://www.cancer.gov/publications/dictionaries/cancer-drug/def/792549|work=NCI Drug Dictionary|publisher=National Cancer Institute|access-date=2020-11-29|archive-date=2021-01-10|archive-url=https://web.archive.org/web/20210110060225/https://www.cancer.gov/publications/dictionaries/cancer-drug/def/792549|dead-url=no}}
* {{Cite web|title=Gilteritinib fumarate|url=https://www.cancer.gov/about-cancer/treatment/drugs/gilteritinibfumarate|publisher=National Cancer Institute|access-date=2020-11-29|archive-date=2021-01-12|archive-url=https://web.archive.org/web/20210112185851/https://www.cancer.gov/about-cancer/treatment/drugs/gilteritinibfumarate|dead-url=no}}
{{細胞外化療藥物}}
[[Category:罕用药|Category:罕用药]]
[[Category:酪氨酸激酶抑制剂|Category:酪氨酸激酶抑制剂]]
[[Category:哌啶|Category:哌啶]]
[[Category:哌嗪|Category:哌嗪]]
[[Category:吡嗪|Category:吡嗪]]
[[Category:安斯泰來製藥|Category:安斯泰來製藥]]